Based on: Sepsis — gene targets, candidate compounds and trials, OSMF Research Tracker (DGIdb, Open Targets, ChEMBL, PubMed and ClinicalTrials.gov data). Numbers are a snapshot taken 8 October 2026; the tracker page is the live version.
Short answer: as of October 2026, the OSMF Research Tracker lists 55 candidate interventions for sepsis that are either approved medicines or have at least one registered clinical trial, built on 12 druggable gene targets, with 14 recent trials on ClinicalTrials.gov. 0 are already approved medicines, for this condition or another one; where the approval is for a different condition, the trial is testing a new use, which is what drug repurposing means. Being in a trial says an intervention is being studied, not that it works; that is what the trial is for.
Which candidates have the most trial activity?
Ranked by the number of registered trials the tracker found. Each trial ID links to the registry entry, where you can read the design, status and sponsor.
- Albumin — 1 registered trial · investigational · NCT02219165
- Amiodarone i.v. — 1 registered trial · investigational · NCT03029169
- Anisodamine hydrobromide combined with heparin — 1 registered trial · investigational · NCT05634057
- Antibiotic — 1 registered trial · investigational · NCT01728363
- Antibody-Drug Conjugate — 1 registered trial · investigational · NCT05349383
- APX001 — 1 registered trial · investigational · NCT04148287
- Blood Collection — 1 registered trial · investigational · NCT04169412
- Breath sample collection — 1 registered trial · investigational · NCT03497182
- C1-esterase inhibitor — 1 registered trial · investigational · NCT01766414
- Chlorhexidine Gluconate Skin Cleanser — 1 registered trial · investigational · NCT01817075
- Chlorhexidine Topical Cream — 1 registered trial · investigational · NCT06002295
- Classic description of acid-base status — 1 registered trial · investigational · NCT03503214
Which gene targets are these built on?
The tracker starts from genes with evidence of being druggable in sepsis and asks which compounds act on them. Each symbol links to its DGIdb entry, which lists the interacting drugs and the papers behind them: ADRB1, CD14, F3, HMGB1, IL1B, IL6, NR3C1, PDCD1, PROC, THBD, TLR4, TNF.
Which trials are registered?
- Evaluation of Diagnostic Accuracy and Clinical Performance of the UllCORE Bloodstream Infection (BSI) Test NCT07859852 · Recruiting · started 2026-09-21
- THE ROLE OF PANCREATIC STONE PROTEIN (PSP) AND PSP-GUIDED EARLY MEROPENEM TREATMENT TO MITIGATE SEPSIS RISK AT THE EMERGENCY DEPARTMENT: THE PROMISE DOUBLE BLIND, PHASE III, RANDOMIZED CONTROLLED CLINICAL TRIAL NCT07813767 · Recruiting · Phase PHASE3 · started 2026-10-01
- Risk Factors for Adverse Outcomes in Sepsis NCT06541600 · Completed · started 2017-06-01
- Thymalfasin for Immune Recovery in Adults With Sepsis NCT07866118 · Recruiting · Phase NA · started 2026-10-06
- Long-Term Recovery and Quality of Life in Sepsis Survivors NCT07863128 · Recruiting · started 2026-09-01
- Plasma Exchange in Children With Severe Sepsis and Septic Shock NCT07706413 · Recruiting · Phase NA · started 2026-08-01
- Direct In-Scope Suction Versus Standard Flexible Ureterorenoscopy NCT07864194 · Recruiting · Phase NA · started 2026-07-07
- Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia NCT03138733 · Completed · Phase PHASE3 · started 2018-08-26
- Microbiome and Enteric Signatures in Sepsis-associated Hepatorenal Injury NCT07735182 · Recruiting · started 2026-02-15
- Non-invasive Hemodynamic Optimization of Sepsis in Internal Medicine: a Randomized Study Comparing Therapy Guided by Non-invasive Hemodynamic Indices Versus Standard of Care. NCT07863323 · Recruiting · Phase NA · started 2025-06-03
How to read this
Evidence is graded on the tracker page in three tiers: clinical (tested in people), mechanistic (a documented action on the target) and correlative (an association in the literature). Most candidates sit in the lower tiers, and many trials are small or early-phase. The purpose of this list is to show where the research is, with sources, so that patients, clinicians and researchers can look further; it is not a ranking of what to take.
Related on this site
Research information, not medical advice. Decisions about any medicine belong with you and your clinician. The underlying data are open (CC BY 4.0) and refreshed daily; this note was generated from the tracker page on 8 October 2026.